Clinical trial
GW572016 For Treatment Of Refractory Metastatic Breast Cancer
NCT00062686 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00062686 |
|---|---|
| Title | GW572016 For Treatment Of Refractory Metastatic Breast Cancer |
| Official title | An Open-Label, Multicenter, Single Arm Phase II Study of Oral GW572016 as Single Agent Therapy in Subjects With Advanced or Metastatic Breast Cancer Who Have Progressed While Receiving HERCEPTIN-Containing Regimens |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Neoplasms, Breast |
| Intervention type | Drug |
| Interventions | GW572016 |
| Enrollment | 200 |
| Start date | Nov 1, 2003 |
| Primary completion | Feb 1, 2005 |
| Completion | Feb 1, 2005 |
| First posted | Jun 12, 2003 |
| Last update posted | Apr 15, 2015 |
| Countries | Argentina, France, Germany, United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: